TCG LABS
TCG LABS is a Pre-seed, Seed, Series A, Series B, Series C+ and other fund in the US and China investing in Healthcare, oncology, immunology, cardiometabolism and therapeutics.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+, other
- Sectors
- Healthcare, oncology, immunology, cardiometabolism, therapeutics
- Invests in
- US-wide, China
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2024
- Assets under management
- $800M
Check size not disclosed
Thesis
TCG Labs-Soleil is a venture-biotech firm that integrates a venture fund with an R&D hub to discover, develop, and advance single-asset therapeutic programs. Their strategy focuses on efficiently translating scientific insights into potential treatments for serious diseases, particularly in oncology, immunology, and cardiometabolism. They incubate and develop single-asset biotechs from ideation through clinical proof of concept, aiming to streamline drug development and reduce financing complexities. TCG Labs-Soleil has raised approximately $800 million across two funds, with Fund I being a $400 million early-stage venture capital fund. Their investment focus is on early-stage development, including pre-seed, seed, and Series A-C stages, guiding assets often through Phase II trials. The firm's geographic scope is primarily the United States, with headquarters in South San Francisco, California, and expanded R&D capabilities in Shanghai, China.
Common questions
Does TCG LABS invest at the Pre-seed stage?
Yes. TCG LABS lists Pre-seed, Seed, Series A, Series B, Series C+ and other among the stages it invests in.
Where does TCG LABS invest?
TCG LABS invests in the US and China.